Annual report pursuant to Section 13 and 15(d)

Net Loss Per Share - Schedule of potentially issuable common shares (Details)

v3.24.0.1
Net Loss Per Share - Schedule of potentially issuable common shares (Details) - shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total common stock equivalents 3,597,217 4,407,366
Conversion of Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total common stock equivalents [1]   855,186
Warrants to Purchase Common Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total common stock equivalents [1] 853,330 853,330
PSUs, RSUs and Options to Purchase Common Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total common stock equivalents [1] 2,160,554 2,115,517
Right to Receive Earnout Shares [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total common stock equivalents [1] 583,333 583,333
[1] Prior period results have been adjusted to reflect the Reverse Stock Split of the Class A Common Stock at a ratio of 1-for-30 that became effective April 24, 2023. See Note 1, “Description of Business and Basis of Presentation,” for details.